The authors propose that the composition of the tumour microenvironment may be driven by genetic influences, such as TP53, which is mutated in IDH-A, but not IDH-O gliomas, and TP53 has been shown to influence several immune pathways, including NF-kB [77]. Here, IDH1 is linked to glioma.